TIG - Mesoblast Completes Deal In China For Stem Cell Heart Therapies

Mesoblast Limited (MESO) announced yesterday that it had entered into a partnership with China based Tasly Pharmaceutical Group. The deal gives Tasly exclusive rights in China for Mesoblast’s allogeneic mesenchymal precursor cell ((MPC)) product candidate MPC-150-IM for the indications of Chronic Heart Failure (CHF) and MPC-25-IC for Acute Myocardial Infarction, a.k.a, heart attack. Mesoblast is currently running two Phase III trials in the U.S. for CHF as indicated in the pipeline below from Mesoblast’s website:

Under the agreement Mesoblast will receive $40,000,000 up front. $20,000,000 as a technology access fee and another